Induction of HLA‑A*33‑restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH

Kawashima,Hidenori; Masaki,Sakae; Kawamura,Marie

doi:10.3892/br.2014.334

Induction of HLA‑A*33‑restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH

Authors:
- Hidenori Kawashima
- Sakae Masaki
- Marie Kawamura
View Affiliations

Affiliations: Shirahama Hamayu Hospital, Shirahama, Wakayama 649‑2211, Japan, Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan
Published online on: August 8, 2014 https://doi.org/10.3892/br.2014.334
Pages: 809-812

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Galectin 9, a ligand of T cell immunoglobulin and mucin domain 3 (TIM‑3), and PINCH, an epithelial‑to‑mesenchymal transition (EMT)‑promoting molecule, are expressed at much higher levels in cancerous lesions of clear cell type renal cell carcinoma (RCC) compared to normal renal tissues, and their expression levels are extremely low in normal tissues, except for galectin 9 in the spleen. Galectin 9‑ and PINCH‑derived peptides have previously been shown to induce human leukocyte antigen (HLA)‑A*2402‑restricted and HLA‑A*0201‑restricted cytotoxic lymphocytes (CTLs) with specific and highly cytotoxic activities toward RCC cells. The present study aimed to identify the peptides that induced HLA‑A*33‑restricted CTLs that exhibited specific and highly cytotoxic activities toward RCC cells. Specific CTLs were induced significantly, as shown by cluster of differentiation 107a degranulation stimulated with VMRC‑RCW renal carcinoma cells. Therefore, peptide vaccines targeting galectin 9 and PINCH appear to be promising for clinical application.

View Figures

View References

1	Umeda T and Niijima T: Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer. 58:1231–1235. 1986. View Article : Google Scholar : PubMed/NCBI
2	Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, et al: Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 57:317–325. 2010. View Article : Google Scholar
3	Kawashima H, Obayashi A, Kawamura M, Masaki S, Tamada S, Iguchi T, Uchida J, Kuratsukuri K, Tanaka T and Nakatani T: Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumor antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides. BJU Int. 113:320–332. 2014. View Article : Google Scholar
4	Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 6:1245–1252. 2005. View Article : Google Scholar : PubMed/NCBI
5	Li Y, Dai C, Wu C and Liu Y: PINCH-1 promotes tubular epithelial-to-mesenchymal transition by interacting with integrin-linked kinase. J Am Soc Nephrol. 18:2534–2543. 2007. View Article : Google Scholar : PubMed/NCBI
6	Chen K, Tu Y, Zhang Y, Blair HC, Zhang L and Wu C: PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells. J Biol Chem. 283:2508–2517. 2008. View Article : Google Scholar : PubMed/NCBI
7	Van Poppel H, Joniau S and Van Gool SW: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 55:1333–1342. 2009.PubMed/NCBI
8	Uemura H, Fujimoto K, Tanaka M, Yoshikawa M, Hirao Y, Uejima S, Yoshikawa K and Itoh K: A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res. 12:1768–1775. 2006. View Article : Google Scholar : PubMed/NCBI
9	Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, et al: A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med. 8:82010. View Article : Google Scholar : PubMed/NCBI
10	Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, et al: WT1 (Wilms’ tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol. 51:519–530. 2007.
11	Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, et al: Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res. 14:6916–6923. 2008. View Article : Google Scholar : PubMed/NCBI
12	Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 18:1254–1261. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lee CS, Cragg M, Glennie M and Johnson P: Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 76:233–247. 2013. View Article : Google Scholar : PubMed/NCBI
14	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mullard A: New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov. 12:489–492. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW and Smyth MJ: Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71:3540–3551. 2011.PubMed/NCBI